Article Abstract

Prof. Yi-Long Wu: Patients on the afatinib arm had a significantly better quality of life according to the data of LUX-Lung 6

Authors: Shannon Zhang


Prof. Yilong Wu (Figure 1) is a consultant oncologist, PhD supervisor, Fellow of American College of Surgeons, Vice President of GGH and Guangdong Academy of Medical Sciences as well as Director of Cancer Center, Director of Guangdong Lung Cancer Institute, member of the Council of the Chinese Anti-cancer Association, Chairman of the Chinese Society of Clinical Oncology (CSCO), Chairman of the Chinese Society of Lung Cancer (CSLC), President of Guangdong Association of Clinical Trial.